These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
458 related items for PubMed ID: 25869887
1. Intermediate rough Brucella abortus S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice. Lalsiamthara J, Gogia N, Goswami TK, Singh RK, Chaudhuri P. Vaccine; 2015 May 21; 33(22):2577-83. PubMed ID: 25869887 [Abstract] [Full Text] [Related]
7. Booster vaccination with safe, modified, live-attenuated mutants of Brucella abortus strain RB51 vaccine confers protective immunity against virulent strains of B. abortus and Brucella canis in BALB/c mice. Truong QL, Cho Y, Kim K, Park BK, Hahn TW. Microbiology (Reading); 2015 Nov 21; 161(11):2137-48. PubMed ID: 26341622 [Abstract] [Full Text] [Related]
8. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Monreal D, Grilló MJ, González D, Marín CM, De Miguel MJ, López-Goñi I, Blasco JM, Cloeckaert A, Moriyón I. Infect Immun; 2003 Jun 21; 71(6):3261-71. PubMed ID: 12761107 [Abstract] [Full Text] [Related]
9. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Vet Microbiol; 2004 Sep 08; 102(3-4):237-45. PubMed ID: 15327798 [Abstract] [Full Text] [Related]
13. Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Ugalde JE, Comerci DJ, Leguizamón MS, Ugalde RA. Infect Immun; 2003 Nov 08; 71(11):6264-9. PubMed ID: 14573645 [Abstract] [Full Text] [Related]
14. Protective and therapeutic efficacy study of divalent fusion protein rL7/L12-Omp25 against B. abortus 544 in presence of IFNγ. Paul S, Peddayelachagiri BV, Nagaraj S, Konduru B, Batra HV. Appl Microbiol Biotechnol; 2018 Oct 08; 102(20):8895-8907. PubMed ID: 30136204 [Abstract] [Full Text] [Related]
15. Lipopolysaccharide as a target for brucellosis vaccine design. Conde-Álvarez R, Arce-Gorvel V, Gil-Ramírez Y, Iriarte M, Grilló MJ, Gorvel JP, Moriyón I. Microb Pathog; 2013 May 08; 58():29-34. PubMed ID: 23219811 [Abstract] [Full Text] [Related]
16. Evaluation of a Brucella melitensis mutant deficient in O-polysaccharide export system ATP-binding protein as a rough vaccine candidate. Wang Z, Niu JR, Wang XL, Wu TL, Cheng J, Lu L, Wu QM. Microbes Infect; 2014 Aug 08; 16(8):633-9. PubMed ID: 25043564 [Abstract] [Full Text] [Related]
17. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J. Infect Immun; 2009 Jan 08; 77(1):436-45. PubMed ID: 18981242 [Abstract] [Full Text] [Related]
18. A potent Brucella abortus 2308 Δery live vaccine allows for the differentiation between natural and vaccinated infection. Zhang J, Yin S, Guo F, Meng R, Chen C, Zhang H, Li Z, Fu Q, Shi H, Hu S, Ni W, Li T, Zhang K. J Microbiol; 2014 Aug 08; 52(8):681-8. PubMed ID: 24994009 [Abstract] [Full Text] [Related]